Sector Expert: Elemer Piros

Cantor Fitzgerald

Image: Elemer Piros

Elemer Piros has ranked among the top analysts in various surveys, including ranking as the top biotechnology analyst by the Wall Street Journal in 2006 and by the Financial Times in 2010, based on stock portfolio performance. He has served as a senior biotechnology analyst at Ladenburg Thalmann, and as a biotechnology research analyst with Spear, Leeds & Kellogg/Goldman Sachs. Before serving as an analyst, Piros spent eight years conducting research in biophysics, biochemistry and molecular biology at Cornell University and the University of California, Los Angeles. He holds a doctorate in neurosciences from UCLA, a bachelor's degree in biology from UCLA, and a bachelor's degree in mathematics and technology from Eotvos Lorand University in Budapest.

Recent Interviews

Do You Have the Guts to Take On Cutting-Edge Biotech Like This VC? (12/13/12)

With the odds stacked against a drug entering clinical trials, investors need to be assured that the upside will be momentous when success does come. Burrill & Co. Managing Director Elemer Piros leverages science and the unmet needs of patients with his extensive knowledge of the capital markets to bring lower-risk, higher-return ideas to investors. In this interview with The Life Sciences Report, Piros explains his investment thesis and zeroes in on best bets.

Recent Quotes

"PVCT's phase 2 trial results for PV-10 are very encouraging."

— Elemer Piros, Cantor Fitzgerald (6/26/12)
more >

"ONCS announced positive results in its single-arm phase 4 trial."

— Elemer Piros, Rodman & Renshaw (4/20/12)
more >

"ONCS' DNA IL-12 is one of the best characterized and potent anti-tumor cytokines."

— Elemer Piros, Rodman & Renshaw (4/11/12)
more >

"We maintain our Market Outperform rating for PVCT."

— Elemer Piros, Rodman & Renshaw (3/26/12)
more >

Due to permission requirements, not all quotes are shown.